glp-1 obesity injector components Advances in receptor agonists delivery systems for and diabetes GLP-1 Therapy Part 1: Setting
Description
Shirakawa, J
Soy free
Researchers found that about 44% of users reported at least one side effect, with gastrointestinal symptoms remaining the most common
doi: 10.1038/s41591-025-04106-7
Semaglutide is a close second with a longer safety track record
